NCT03118128View on ClinicalTrials.gov

Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia

NACompletedINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

December 1, 2016

Study Completion Date

April 30, 2017

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG

Metformin

Metformin 850 mg PO three times a day plus prednisone in one 7-days cycle as pre-treatment and during the 28 days induction remission treatment, consolidation therapy and maintenance

All Listed Sponsors

lead

Hospital General de Mexico

OTHER_GOV

NCT03118128 - Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter